| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MDS.20856 |
| P698 | PubMed publication ID | 16550541 |
| P50 | author | Susan R Heckbert | Q88077554 |
| William T. Longstreth | Q123220049 | ||
| Walter A. Kukull | Q37386731 | ||
| P2093 | author name string | Phillip D Swanson | |
| Gary M Franklin | |||
| Harvey Checkoway | |||
| Mary Anne Rossing | |||
| Terri Smith-Weller | |||
| Thanh G Ton | |||
| P2860 | cites work | The Risk of Myocardial Infarction Associated With Antihypertensive Drug Therapies | Q38508613 |
| Cytokines in neurodegeneration and repair | Q40420561 | ||
| Cyclooxygenases and the central nervous system | Q41646498 | ||
| Effects of nonsteroidal antiinflammatory drugs on oxidative pathways in A/J mice | Q42490541 | ||
| Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats | Q28195213 | ||
| Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease | Q28199468 | ||
| Parkinson's disease: mechanisms and models | Q29547424 | ||
| Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro | Q31431931 | ||
| Parkinson's disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake | Q34522327 | ||
| RETRACTED: A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide | Q36438395 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| inflammation | Q101991 | ||
| P304 | page(s) | 964-9 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Movement Disorders | Q1486418 |
| P1476 | title | Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease | |
| P478 | volume | 21 |
| Q50647765 | Alismol, a Sesquiterpenoid Isolated from Vladimiria souliei, Suppresses Proinflammatory Mediators in Lipopolysaccharide-Stimulated Microglia. |
| Q48171351 | An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition. |
| Q23724883 | An overview of clinical pharmacology of Ibuprofen |
| Q22241651 | Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis |
| Q37425099 | Autoimmune disease and risk for Parkinson disease: a population-based case-control study. |
| Q38910480 | Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study |
| Q33836942 | Cyclooxygenase and Neuroinflammation in Parkinsons Disease Neurodegeneration |
| Q36847262 | Death in the substantia nigra: a motor tragedy |
| Q38784992 | Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability |
| Q64776622 | Emerging therapies in Parkinson disease - repurposed drugs and new approaches |
| Q34437648 | Formulations of hormone therapy and risk of Parkinson's disease |
| Q28388674 | Gene-environment interactions: key to unraveling the mystery of Parkinson's disease |
| Q38693732 | Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease |
| Q41262976 | Immune responses in Parkinson's disease: interplay between central and peripheral immune systems |
| Q37069901 | Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship |
| Q41917715 | Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease |
| Q37735815 | Inflammatory response in Parkinsonism. |
| Q37401280 | Innate and adaptive immunity for the pathobiology of Parkinson's disease |
| Q26795984 | Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies |
| Q55240777 | Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. |
| Q29547835 | Microglia-mediated neurotoxicity: uncovering the molecular mechanisms |
| Q37322333 | Microglial ion channels as potential targets for neuroprotection in Parkinson's disease |
| Q55023794 | Molecular and Clinical Issues about the Risk of Venous Thromboembolism in Older Patients: A Focus on Parkinson's Disease and Parkinsonism. |
| Q57950713 | NSAID use and risk of Parkinson disease: a population-based case-control study |
| Q37591516 | NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies |
| Q38078895 | Neural and immune mechanisms in the pathogenesis of Parkinson's disease. |
| Q37241917 | Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration |
| Q29616300 | Neuroinflammation in Parkinson's disease: a target for neuroprotection? |
| Q26801035 | Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs |
| Q36537780 | Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease |
| Q37267160 | Non-genetic factors associated with the risk of Parkinson's disease in Iranian patients |
| Q57045903 | Non-steroidal anti-inflammatory drugs and risk of Parkinson's disease in the elderly population: a meta-analysis |
| Q24235107 | Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies |
| Q28476681 | Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques |
| Q58739806 | Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis |
| Q28397422 | PACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in mice |
| Q37015945 | Parkin deficiency increases vulnerability to inflammation-related nigral degeneration |
| Q38055457 | Parkinson's disease: evidence for environmental risk factors |
| Q37878282 | Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. |
| Q37741285 | Pharmacological therapy in Parkinson's disease: focus on neuroprotection |
| Q48474282 | Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study |
| Q36773965 | RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells |
| Q34353167 | Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study |
| Q28392767 | Rotenone and paraquat do not directly activate microglia or induce inflammatory cytokine release |
| Q48145970 | Sodium salicylate protects against rotenone-induced parkinsonism in rats |
| Q37886152 | Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: a new anti-Parkinson drug? |
| Q37302453 | Targets for neuroprotection in Parkinson's disease |
| Q36048230 | The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research |
| Q34557246 | The endotoxin-induced neuroinflammation model of Parkinson's disease. |
| Q30244421 | The epidemiology of Parkinson's disease: risk factors and prevention |
| Q21129436 | The promise of neuroprotective agents in Parkinson's disease |
| Q38105903 | The role of inflammation in sporadic and familial Parkinson's disease |
| Q38115703 | The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson's disease: focus on astrocytes |
| Q38860761 | The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration |
| Q36453886 | Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation |
| Q37680121 | Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction |
| Q46132067 | Updates on immunity and inflammation in Parkinson disease pathology |
| Q24594751 | Use of ibuprofen and risk of Parkinson disease |
| Q34505182 | Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study |
Search more.